ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global MET Inhibitor Drugs Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-23X11266
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global MET Inhibitor Drugs Market Research Report 2022
BUY CHAPTERS

Global MET Inhibitor Drugs Market Research Report 2025

Code: QYRE-Auto-23X11266
Report
January 2025
Pages:79
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Abbott Laboratories
Johnson and Johnson
Novartis International AG
Eli Lilly and Company
Takeda Pharmaceutical Company
GlaxoSmithKline PLC
Amgen Inc
Bristol–Myers Squibb
Daiichi Sankyo Company Limited
Pfizer Inc., Merck & Co.

MET Inhibitor Drugs Market Size

The global market for MET Inhibitor Drugs was valued at US$ 3372 million in the year 2024 and is projected to reach a revised size of US$ 5810 million by 2031, growing at a CAGR of 8.2% during the forecast period.

MET Inhibitor Drugs Market

MET Inhibitor Drugs Market

MET inhibitor drugs are a class of pharmaceutical agents designed to target and inhibit the activity of the MET receptor tyrosine kinase. The MET receptor, also known as c-MET or hepatocyte growth factor receptor (HGFR), plays a crucial role in cell growth, proliferation, migration, and survival. Abnormal activation or overexpression of MET is often associated with cancer development and progression, making MET inhibitors a promising approach in cancer therapy.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for MET Inhibitor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding MET Inhibitor Drugs.
The MET Inhibitor Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global MET Inhibitor Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the MET Inhibitor Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of MET Inhibitor Drugs Market Report

Report Metric Details
Report Name MET Inhibitor Drugs Market
Accounted market size in year US$ 3372 million
Forecasted market size in 2031 US$ 5810 million
CAGR 8.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • C-Met Biological Inhibitors
  • Small Molecule C-Met Inhibitors
  • C-Met Antagonist Antibodies
  • HGF Antagonist Antibodies
  • Kringle Variant Antagonists
Segment by Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Abbott Laboratories, Johnson and Johnson, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co., Takeda Pharmaceutical Company, GlaxosmithKline plc, Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Company, Limited
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of MET Inhibitor Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of MET Inhibitor Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is MET Inhibitor Drugs Market growing?

Ans: The MET Inhibitor Drugs Market witnessing a CAGR of 8.2% during the forecast period 2025-2031.

What is the MET Inhibitor Drugs Market size in 2031?

Ans: The MET Inhibitor Drugs Market size in 2031 will be US$ 5810 million.

Who are the main players in the MET Inhibitor Drugs Market report?

Ans: The main players in the MET Inhibitor Drugs Market are Abbott Laboratories, Johnson and Johnson, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co., Takeda Pharmaceutical Company, GlaxosmithKline plc, Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Company, Limited

What are the Application segmentation covered in the MET Inhibitor Drugs Market report?

Ans: The Applications covered in the MET Inhibitor Drugs Market report are Hospital Pharmacies, Retail Pharmacies, Others

What are the Type segmentation covered in the MET Inhibitor Drugs Market report?

Ans: The Types covered in the MET Inhibitor Drugs Market report are C-Met Biological Inhibitors, Small Molecule C-Met Inhibitors, C-Met Antagonist Antibodies, HGF Antagonist Antibodies, Kringle Variant Antagonists

Recommended Reports

Cancer Drug Markets

Targeted Therapy Drugs

Antagonists & Inhibitors

1 MET Inhibitor Drugs Market Overview
1.1 Product Definition
1.2 MET Inhibitor Drugs by Type
1.2.1 Global MET Inhibitor Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 C-Met Biological Inhibitors
1.2.3 Small Molecule C-Met Inhibitors
1.2.4 C-Met Antagonist Antibodies
1.2.5 HGF Antagonist Antibodies
1.2.6 Kringle Variant Antagonists
1.3 MET Inhibitor Drugs by Application
1.3.1 Global MET Inhibitor Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Others
1.4 Global MET Inhibitor Drugs Market Size Estimates and Forecasts
1.4.1 Global MET Inhibitor Drugs Revenue 2020-2031
1.4.2 Global MET Inhibitor Drugs Sales 2020-2031
1.4.3 Global MET Inhibitor Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 MET Inhibitor Drugs Market Competition by Manufacturers
2.1 Global MET Inhibitor Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global MET Inhibitor Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global MET Inhibitor Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of MET Inhibitor Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of MET Inhibitor Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of MET Inhibitor Drugs, Product Type & Application
2.7 Global Key Manufacturers of MET Inhibitor Drugs, Date of Enter into This Industry
2.8 Global MET Inhibitor Drugs Market Competitive Situation and Trends
2.8.1 Global MET Inhibitor Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest MET Inhibitor Drugs Players Market Share by Revenue
2.8.3 Global MET Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global MET Inhibitor Drugs Market Scenario by Region
3.1 Global MET Inhibitor Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global MET Inhibitor Drugs Sales by Region: 2020-2031
3.2.1 Global MET Inhibitor Drugs Sales by Region: 2020-2025
3.2.2 Global MET Inhibitor Drugs Sales by Region: 2026-2031
3.3 Global MET Inhibitor Drugs Revenue by Region: 2020-2031
3.3.1 Global MET Inhibitor Drugs Revenue by Region: 2020-2025
3.3.2 Global MET Inhibitor Drugs Revenue by Region: 2026-2031
3.4 North America MET Inhibitor Drugs Market Facts & Figures by Country
3.4.1 North America MET Inhibitor Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America MET Inhibitor Drugs Sales by Country (2020-2031)
3.4.3 North America MET Inhibitor Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe MET Inhibitor Drugs Market Facts & Figures by Country
3.5.1 Europe MET Inhibitor Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe MET Inhibitor Drugs Sales by Country (2020-2031)
3.5.3 Europe MET Inhibitor Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific MET Inhibitor Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific MET Inhibitor Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific MET Inhibitor Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific MET Inhibitor Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America MET Inhibitor Drugs Market Facts & Figures by Country
3.7.1 Latin America MET Inhibitor Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America MET Inhibitor Drugs Sales by Country (2020-2031)
3.7.3 Latin America MET Inhibitor Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa MET Inhibitor Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa MET Inhibitor Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa MET Inhibitor Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa MET Inhibitor Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global MET Inhibitor Drugs Sales by Type (2020-2031)
4.1.1 Global MET Inhibitor Drugs Sales by Type (2020-2025)
4.1.2 Global MET Inhibitor Drugs Sales by Type (2026-2031)
4.1.3 Global MET Inhibitor Drugs Sales Market Share by Type (2020-2031)
4.2 Global MET Inhibitor Drugs Revenue by Type (2020-2031)
4.2.1 Global MET Inhibitor Drugs Revenue by Type (2020-2025)
4.2.2 Global MET Inhibitor Drugs Revenue by Type (2026-2031)
4.2.3 Global MET Inhibitor Drugs Revenue Market Share by Type (2020-2031)
4.3 Global MET Inhibitor Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global MET Inhibitor Drugs Sales by Application (2020-2031)
5.1.1 Global MET Inhibitor Drugs Sales by Application (2020-2025)
5.1.2 Global MET Inhibitor Drugs Sales by Application (2026-2031)
5.1.3 Global MET Inhibitor Drugs Sales Market Share by Application (2020-2031)
5.2 Global MET Inhibitor Drugs Revenue by Application (2020-2031)
5.2.1 Global MET Inhibitor Drugs Revenue by Application (2020-2025)
5.2.2 Global MET Inhibitor Drugs Revenue by Application (2026-2031)
5.2.3 Global MET Inhibitor Drugs Revenue Market Share by Application (2020-2031)
5.3 Global MET Inhibitor Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Abbott Laboratories
6.1.1 Abbott Laboratories Company Information
6.1.2 Abbott Laboratories Description and Business Overview
6.1.3 Abbott Laboratories MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Abbott Laboratories MET Inhibitor Drugs Product Portfolio
6.1.5 Abbott Laboratories Recent Developments/Updates
6.2 Johnson and Johnson
6.2.1 Johnson and Johnson Company Information
6.2.2 Johnson and Johnson Description and Business Overview
6.2.3 Johnson and Johnson MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Johnson and Johnson MET Inhibitor Drugs Product Portfolio
6.2.5 Johnson and Johnson Recent Developments/Updates
6.3 Novartis International AG
6.3.1 Novartis International AG Company Information
6.3.2 Novartis International AG Description and Business Overview
6.3.3 Novartis International AG MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis International AG MET Inhibitor Drugs Product Portfolio
6.3.5 Novartis International AG Recent Developments/Updates
6.4 Eli Lilly and Company
6.4.1 Eli Lilly and Company Company Information
6.4.2 Eli Lilly and Company Description and Business Overview
6.4.3 Eli Lilly and Company MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Eli Lilly and Company MET Inhibitor Drugs Product Portfolio
6.4.5 Eli Lilly and Company Recent Developments/Updates
6.5 Pfizer Inc., Merck & Co.
6.5.1 Pfizer Inc., Merck & Co. Company Information
6.5.2 Pfizer Inc., Merck & Co. Description and Business Overview
6.5.3 Pfizer Inc., Merck & Co. MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Inc., Merck & Co. MET Inhibitor Drugs Product Portfolio
6.5.5 Pfizer Inc., Merck & Co. Recent Developments/Updates
6.6 Takeda Pharmaceutical Company
6.6.1 Takeda Pharmaceutical Company Company Information
6.6.2 Takeda Pharmaceutical Company Description and Business Overview
6.6.3 Takeda Pharmaceutical Company MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Takeda Pharmaceutical Company MET Inhibitor Drugs Product Portfolio
6.6.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.7 GlaxosmithKline plc
6.7.1 GlaxosmithKline plc Company Information
6.7.2 GlaxosmithKline plc Description and Business Overview
6.7.3 GlaxosmithKline plc MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 GlaxosmithKline plc MET Inhibitor Drugs Product Portfolio
6.7.5 GlaxosmithKline plc Recent Developments/Updates
6.8 Amgen Inc.
6.8.1 Amgen Inc. Company Information
6.8.2 Amgen Inc. Description and Business Overview
6.8.3 Amgen Inc. MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Amgen Inc. MET Inhibitor Drugs Product Portfolio
6.8.5 Amgen Inc. Recent Developments/Updates
6.9 Bristol Myers Squibb
6.9.1 Bristol Myers Squibb Company Information
6.9.2 Bristol Myers Squibb Description and Business Overview
6.9.3 Bristol Myers Squibb MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Bristol Myers Squibb MET Inhibitor Drugs Product Portfolio
6.9.5 Bristol Myers Squibb Recent Developments/Updates
6.10 Daiichi Sankyo Company, Limited
6.10.1 Daiichi Sankyo Company, Limited Company Information
6.10.2 Daiichi Sankyo Company, Limited Description and Business Overview
6.10.3 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product Portfolio
6.10.5 Daiichi Sankyo Company, Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 MET Inhibitor Drugs Industry Chain Analysis
7.2 MET Inhibitor Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 MET Inhibitor Drugs Production Mode & Process Analysis
7.4 MET Inhibitor Drugs Sales and Marketing
7.4.1 MET Inhibitor Drugs Sales Channels
7.4.2 MET Inhibitor Drugs Distributors
7.5 MET Inhibitor Drugs Customer Analysis
8 MET Inhibitor Drugs Market Dynamics
8.1 MET Inhibitor Drugs Industry Trends
8.2 MET Inhibitor Drugs Market Drivers
8.3 MET Inhibitor Drugs Market Challenges
8.4 MET Inhibitor Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Abbott Laboratories
Johnson and Johnson
Novartis International AG
Eli Lilly and Company
Takeda Pharmaceutical Company
GlaxoSmithKline PLC
Amgen Inc
Bristol–Myers Squibb
Daiichi Sankyo Company Limited
Pfizer Inc., Merck & Co.
List of Tables
 Table 1. Global MET Inhibitor Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global MET Inhibitor Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global MET Inhibitor Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global MET Inhibitor Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global MET Inhibitor Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global MET Inhibitor Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global MET Inhibitor Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market MET Inhibitor Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of MET Inhibitor Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of MET Inhibitor Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of MET Inhibitor Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of MET Inhibitor Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global MET Inhibitor Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in MET Inhibitor Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global MET Inhibitor Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global MET Inhibitor Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global MET Inhibitor Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global MET Inhibitor Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global MET Inhibitor Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global MET Inhibitor Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global MET Inhibitor Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global MET Inhibitor Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global MET Inhibitor Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America MET Inhibitor Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America MET Inhibitor Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America MET Inhibitor Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America MET Inhibitor Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America MET Inhibitor Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe MET Inhibitor Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe MET Inhibitor Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe MET Inhibitor Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe MET Inhibitor Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe MET Inhibitor Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific MET Inhibitor Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific MET Inhibitor Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific MET Inhibitor Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific MET Inhibitor Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific MET Inhibitor Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America MET Inhibitor Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America MET Inhibitor Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America MET Inhibitor Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America MET Inhibitor Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America MET Inhibitor Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa MET Inhibitor Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa MET Inhibitor Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa MET Inhibitor Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa MET Inhibitor Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa MET Inhibitor Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global MET Inhibitor Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global MET Inhibitor Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global MET Inhibitor Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global MET Inhibitor Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global MET Inhibitor Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global MET Inhibitor Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global MET Inhibitor Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global MET Inhibitor Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global MET Inhibitor Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global MET Inhibitor Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global MET Inhibitor Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global MET Inhibitor Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global MET Inhibitor Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global MET Inhibitor Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global MET Inhibitor Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global MET Inhibitor Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global MET Inhibitor Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global MET Inhibitor Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global MET Inhibitor Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global MET Inhibitor Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. Abbott Laboratories Company Information
 Table 71. Abbott Laboratories Description and Business Overview
 Table 72. Abbott Laboratories MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Abbott Laboratories MET Inhibitor Drugs Product
 Table 74. Abbott Laboratories Recent Developments/Updates
 Table 75. Johnson and Johnson Company Information
 Table 76. Johnson and Johnson Description and Business Overview
 Table 77. Johnson and Johnson MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Johnson and Johnson MET Inhibitor Drugs Product
 Table 79. Johnson and Johnson Recent Developments/Updates
 Table 80. Novartis International AG Company Information
 Table 81. Novartis International AG Description and Business Overview
 Table 82. Novartis International AG MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Novartis International AG MET Inhibitor Drugs Product
 Table 84. Novartis International AG Recent Developments/Updates
 Table 85. Eli Lilly and Company Company Information
 Table 86. Eli Lilly and Company Description and Business Overview
 Table 87. Eli Lilly and Company MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Eli Lilly and Company MET Inhibitor Drugs Product
 Table 89. Eli Lilly and Company Recent Developments/Updates
 Table 90. Pfizer Inc., Merck & Co. Company Information
 Table 91. Pfizer Inc., Merck & Co. Description and Business Overview
 Table 92. Pfizer Inc., Merck & Co. MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Pfizer Inc., Merck & Co. MET Inhibitor Drugs Product
 Table 94. Pfizer Inc., Merck & Co. Recent Developments/Updates
 Table 95. Takeda Pharmaceutical Company Company Information
 Table 96. Takeda Pharmaceutical Company Description and Business Overview
 Table 97. Takeda Pharmaceutical Company MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Takeda Pharmaceutical Company MET Inhibitor Drugs Product
 Table 99. Takeda Pharmaceutical Company Recent Developments/Updates
 Table 100. GlaxosmithKline plc Company Information
 Table 101. GlaxosmithKline plc Description and Business Overview
 Table 102. GlaxosmithKline plc MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. GlaxosmithKline plc MET Inhibitor Drugs Product
 Table 104. GlaxosmithKline plc Recent Developments/Updates
 Table 105. Amgen Inc. Company Information
 Table 106. Amgen Inc. Description and Business Overview
 Table 107. Amgen Inc. MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Amgen Inc. MET Inhibitor Drugs Product
 Table 109. Amgen Inc. Recent Developments/Updates
 Table 110. Bristol Myers Squibb Company Information
 Table 111. Bristol Myers Squibb Description and Business Overview
 Table 112. Bristol Myers Squibb MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Bristol Myers Squibb MET Inhibitor Drugs Product
 Table 114. Bristol Myers Squibb Recent Developments/Updates
 Table 115. Daiichi Sankyo Company, Limited Company Information
 Table 116. Daiichi Sankyo Company, Limited Description and Business Overview
 Table 117. Daiichi Sankyo Company, Limited MET Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Daiichi Sankyo Company, Limited MET Inhibitor Drugs Product
 Table 119. Daiichi Sankyo Company, Limited Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. MET Inhibitor Drugs Distributors List
 Table 123. MET Inhibitor Drugs Customers List
 Table 124. MET Inhibitor Drugs Market Trends
 Table 125. MET Inhibitor Drugs Market Drivers
 Table 126. MET Inhibitor Drugs Market Challenges
 Table 127. MET Inhibitor Drugs Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of MET Inhibitor Drugs
 Figure 2. Global MET Inhibitor Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global MET Inhibitor Drugs Market Share by Type: 2024 & 2031
 Figure 4. C-Met Biological Inhibitors Product Picture
 Figure 5. Small Molecule C-Met Inhibitors Product Picture
 Figure 6. C-Met Antagonist Antibodies Product Picture
 Figure 7. HGF Antagonist Antibodies Product Picture
 Figure 8. Kringle Variant Antagonists Product Picture
 Figure 9. Global MET Inhibitor Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global MET Inhibitor Drugs Market Share by Application: 2024 & 2031
 Figure 11. Hospital Pharmacies
 Figure 12. Retail Pharmacies
 Figure 13. Others
 Figure 14. Global MET Inhibitor Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global MET Inhibitor Drugs Market Size (2020-2031) & (US$ Million)
 Figure 16. Global MET Inhibitor Drugs Sales (2020-2031) & (K Units)
 Figure 17. Global MET Inhibitor Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 18. MET Inhibitor Drugs Report Years Considered
 Figure 19. MET Inhibitor Drugs Sales Share by Manufacturers in 2024
 Figure 20. Global MET Inhibitor Drugs Revenue Share by Manufacturers in 2024
 Figure 21. Global 5 and 10 Largest MET Inhibitor Drugs Players: Market Share by Revenue in MET Inhibitor Drugs in 2024
 Figure 22. MET Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 23. Global MET Inhibitor Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 24. North America MET Inhibitor Drugs Sales Market Share by Country (2020-2031)
 Figure 25. North America MET Inhibitor Drugs Revenue Market Share by Country (2020-2031)
 Figure 26. United States MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Canada MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Europe MET Inhibitor Drugs Sales Market Share by Country (2020-2031)
 Figure 29. Europe MET Inhibitor Drugs Revenue Market Share by Country (2020-2031)
 Figure 30. Germany MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. France MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. U.K. MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Italy MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Russia MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Asia Pacific MET Inhibitor Drugs Sales Market Share by Region (2020-2031)
 Figure 36. Asia Pacific MET Inhibitor Drugs Revenue Market Share by Region (2020-2031)
 Figure 37. China MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Japan MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. South Korea MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. India MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Australia MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. China Taiwan MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Indonesia MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Thailand MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Malaysia MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America MET Inhibitor Drugs Sales Market Share by Country (2020-2031)
 Figure 47. Latin America MET Inhibitor Drugs Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa MET Inhibitor Drugs Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa MET Inhibitor Drugs Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. UAE MET Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of MET Inhibitor Drugs by Type (2020-2031)
 Figure 57. Global Revenue Market Share of MET Inhibitor Drugs by Type (2020-2031)
 Figure 58. Global MET Inhibitor Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 59. Global Sales Market Share of MET Inhibitor Drugs by Application (2020-2031)
 Figure 60. Global Revenue Market Share of MET Inhibitor Drugs by Application (2020-2031)
 Figure 61. Global MET Inhibitor Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 62. MET Inhibitor Drugs Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global Epidermal Growth Factor Receptor Inhibitors Market Research Report 2024
Global MET TKIs Market Research Report 2024
Global Kinase Inhibitors For Cancer Treatment Market Research Report 2024
Global BRAF Inhibitors Market Research Report 2024
Global VEGF Inhibitors Market Research Report 2024
Global Anticancer Drugs Market Research Report 2025
Global Pan FGFR Inhibitors Market Research Report 2024
Global EGFR TKI Market Research Report 2024
Global C MET HGF Inhibitors Market Research Report 2024
Global Single target MET TKIs Market Research Report 2024
Global Multi target MET TKIs Market Research Report 2024
Global Medical FLT3 Inhibitor Market Research Report 2024
Global Tyrosine Kinase Inhibitors Market Research Report 2024
Global ALK Inhibitors Market Research Report 2024
Global FLT3 Antagonists Market Research Report 2024
Global MEK Inhibitor Market Research Report 2024
JAK1 Inhibitor Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global CDK4 6 Inhibitors Market Research Report 2024
Global Cabozantinib Drugs Market Research Report 2024
Global Integrin Inhibitors Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions